26.07.2010 • Newssales and profitsAshland

Ashland Profit Nearly Triples as Sales Surge

Ashland, the chemical maker and Valvoline brand owner, said on Friday its quarterly profit nearly tripled as volumes and sales rallied across most of its business units. The company not only produces a wide range of chemicals, including industrial glues, but distributes chemicals for its rivals.

Its results are often a key barometer on the health of the overall chemical industry and by extension, the broader economy.

For the third quarter ended on June 30, Ashland posted net income of $148 million, or $1.85 per share, compared with $50 million, or 66 cents per share, a year earlier. Excluding one-time items, including a tax benefit, the company earned $1.22 per share. By that measure, analysts expected earnings of $1.13, according to Thomson Reuters I/B/E/S. Revenue rose 16% to $2.36 billion. Analysts expected $2.30 billion.

The Covington, Ky.-based company said the busy summer driving season helped fuel a 5% jump in sales at the consumer markets unit, which contains the Valvoline oil change business. Across the company, sales rose at three of its five units, with sales falling only slightly at the functional ingredients unit, which makes chemicals for paint, food and medical uses, and the water technologies unit, which supplies materials used in wastewater treatment. Sales in the chemical distribution unit rose 32.2%.

"As we consider the next few quarters, we anticipate sustained, gradual growth of the overall economy," Ashland Chief Executive Officer James O'Brien said in a statement. "We continue to see growth in both volume and sales."

Company

Logo:

Ashland

500 Hercules Road Building 8145
19808 Wilmington, DE
US

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.